Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
xeraya@xeraya.com
+603 2381 8700
Submit a Proposal
proposal@xeraya.com
Back

News & Events

Latest news and events related to our activities and our portfolio partners.
xeraya-logo-retina
  • Xeraya Admin
  • Posted by Xeraya Admin
August 20, 2026
1 min read

Statement By Xeraya

All G Welcomes Xeraya Capital as Strategic Investor to Accelerate Innovation and Growth
  • Xeraya
  • Posted by Xeraya
August 11, 2026
2 min read

All G Welcomes Xeraya Capital as Strategic Investor to Accelerate Innovation and Growth

MEMORANDUM OF UNDERSTANDING (MOU) BETWEEN XERAYA CAPITAL SDN. BHD. AND MIRXES INTERNATIONAL HOLDINGS LIMITED 2
  • Xeraya Admin
  • Posted by Xeraya Admin
October 28, 2025
2 min read

Joint Venture Agreement (JVA) Between Xeraya Capital SDN. BHD. And Mirxes International Holdings Limited

Mirxes Holding Company
  • Xeraya Admin
  • Posted by Xeraya Admin
June 10, 2025
1 min read

Mirxes achieving a market capitalization exceeding USD 1 billion on its first day of trading on the Hong Kong Stock Exchange (HKEX) marks a monumental milestone

  • Xeraya Admin
  • Posted by Xeraya Admin
February 29, 2024
5 min read

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
  • Xeraya Admin
  • Posted by Xeraya Admin
February 29, 2024
5 min read

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

GreenLight Biosciences Announces EPA Registration of Calantha
  • Xeraya Admin
  • Posted by Xeraya Admin
January 4, 2024
6 min read

GreenLight Biosciences Announces EPA Registration of Calantha

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
December 20, 2023
11 min read

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

P2 Science Announces Appointment of Oihana Elizalde as CEO
  • Xeraya Admin
  • Posted by Xeraya Admin
November 27, 2023
4 min read

P2 Science Announces Appointment of Oihana Elizalde as CEO

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
November 8, 2023
7 min read

Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
October 4, 2023
2 min read

RNAi pesticide moves closer to US approval

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
  • Xeraya Admin
  • Posted by Xeraya Admin
September 27, 2023
4 min read

InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
  • Xeraya Admin
  • Posted by Xeraya Admin
August 31, 2023
6 min read

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/ Enmetazobactam Met Criteria for Superiority
  • Xeraya Admin
  • Posted by Xeraya Admin
June 27, 2023
4 min read

Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Foghorn Therapeutics
  • Xeraya Admin
  • Posted by Xeraya Admin
June 27, 2023
5 min read

Test Based on Glycoproteomic Profiles Shows High Sensitivity for Advanced Adenomas

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
May 8, 2023
5 min read

InterVenn Demonstrates Power of Its GlycoVision Platform In Advanced Adenoma and Colorectal Cancer

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
  • Xeraya Admin
  • Posted by Xeraya Admin
March 7, 2023
7 min read

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
  • Xeraya Admin
  • Posted by Xeraya Admin
January 9, 2023
9 min read

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization
  • Xeraya Admin
  • Posted by Xeraya Admin
January 5, 2023
7 min read

InterVenn Biosciences Enters Next Stage with Senior Management Team Updates Focused on Commercialization

annual-dinner-2022
  • Xeraya Admin
  • Posted by Xeraya Admin
December 9, 2022
1 min read

Xeraya Capital's Annual Dinner 2022

mvca-2022
  • Xeraya Admin
  • Posted by Xeraya Admin
December 8, 2022
1 min read

MVCA Awards 2022

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter
  • Xeraya Admin
  • Posted by Xeraya Admin
December 6, 2022
3 min read

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter

Merck to buy Xeraya-backed Imago BioSciences for $1.35b
  • Xeraya Admin
  • Posted by Xeraya Admin
November 22, 2022
3 min read

Merck to buy Xeraya-backed Imago BioSciences for $1.35b

Acutus Medical Obtains MDR CE Mark of the AcQMap 3D Imaging and Mapping Catheter
  • Xeraya Admin
  • Posted by Xeraya Admin
November 3, 2022
3 min read

Acutus Medical achieves $20M milestone in Medtronic deal